ARV-7 Press Release

Precision Antibody is pleased to announce the recent article published in Cancers 2020, by Konig et al entitled “Expression of AR-V7 (androgen receptor variant 7) protein in granular cytoplasmic structures is an independent prognostic factor in prostate cancer patients”. In this collaborative study, researchers at Universitätsklinikum Erlangen utilized anti-ARV-7 antibody from Precision Antibody to examine ARV-7 expression by immunohistochemistry on tumor biopsies from 410 Prostate Cancer (PCa) patients. While many studies in advanced stage PCa focus on the role of nuclear ARV-7, the present study established for the first time the prognostic value of ARV-7 staining in cytoplasm and in cytoplasmic granules expression as being associated with relapse free survival (RFS) in PCa. AR-V7 cytoplasmic staining, as shown in the photomicrograph, was associated with shorter RFS while AR-V7 granular staining was associated with longer RFS. Sub-group analysis showed AR-V7 granular staining to be an independent prognostic factor in younger patients (≤65), patients with negative cytokeratin 20 staining and patients with perineural invasion. Altogether, AR-V7 protein in granular cytoplasmic structures appears to be an independent prognostic factor for RFS in prostate cancer patients.


PCa is the second most common cancer and the fifth most common cause of cancer-associated death in men worldwide. PCa is dependent on androgen receptor (AR) signaling at almost all stages of the disease. Based on this AR signaling dependency, most PCa therapeutic approaches target the androgen receptor, androgen biosynthesis and/or the interaction of the AR with androgens. However, over time therapeutic resistance to AR-targeted therapies may develop due to AR mutations, AR amplification or AR splice variants. AR-V7 splice variant appears to be the most clinically relevant variant hence most studied [11].

The success of studies of ARV-7 protein expression in tumor tissue and circulating tumor cells is reliant upon the development of a highly specific and sensitive cleavage site-specific antibody that recognizes only the ARV-7 and not the full-length AR or the other splice variants.

Precision Antibody is the leader in the development of modification site-specific antibodies such as anti-ARV-7. The development of modification site-specific antibodies requires precise antigen design, well-thought-out application-compatible screening methods and the selection of high affinity, low off-rate antibodies measured by SPR or BLI technologies such as Octet or Biacore.

Precision Antibody put this strategy in place to develop the anti-ARV-7 antibody used here and is happy to have contributed to this prostate cancer study with our colleagues in Germany.

To read the full research paper Cancers 2020, 12(9), 2639, visit (
The ARV-7 antibody used in this study can be found in our Purchase Antibodies catalogue under Product Number: AG10008

How can we help?
Design Your Project
Request A Quote
Purchase antibodies